Geoghegan J, Pappas T N
Department of General and Visceral Surgery, Friedrich-Schiller University Jena, Germany.
Ann Surg. 1997 Feb;225(2):145-54. doi: 10.1097/00000658-199702000-00002.
The authors review clinical applications of gut-derived peptides as diagnostic and therapeutic agents.
An increasing number of gut peptides have been evaluated for clinical use. Earlier uses as diagnostic agents have been complemented more recently by increasing application of gut peptides as therapeutic agents.
The authors conducted a literature review.
Current experience with clinical use of gut peptides is described. Initial clinical applications focused on using secretomotor effects of gut peptides in diagnostic tests, many of which have now fallen into disuse. More recently, attention has been directed toward harnessing these secretomotor effects for therapeutic use in a variety of disorders, and also using the trophic effects of gut peptides to modulate gut mucosal growth in benign and malignant disease. Gut peptides have been evaluated in a variety of other clinical situations including use as adjuncts to imaging techniques, and modification of behaviors such as feeding and panic disorder.
Gut peptides have been used successfully in an increasing variety of clinical conditions. Further refinements in analogue and antagonist design are likely to lead to even more selective agents that may have important clinical applications. Further studies are needed to identity and evaluate these new agents.
作者回顾了肠道源性肽作为诊断和治疗药物的临床应用。
越来越多的肠道肽已被评估用于临床。早期作为诊断药物的应用,近来因肠道肽作为治疗药物的应用增加而得到补充。
作者进行了文献综述。
描述了目前肠道肽临床应用的经验。最初的临床应用集中在利用肠道肽的促分泌作用进行诊断测试,其中许多现已不再使用。最近,注意力已转向利用这些促分泌作用在各种疾病中进行治疗,以及利用肠道肽的营养作用调节良性和恶性疾病中的肠道黏膜生长。肠道肽已在各种其他临床情况中进行了评估,包括用作成像技术的辅助手段,以及改变诸如进食和恐慌症等行为。
肠道肽已成功用于越来越多的临床病症。类似物和拮抗剂设计的进一步改进可能会产生更具选择性的药物,可能具有重要的临床应用。需要进一步研究来鉴定和评估这些新药物。